- Conditions
- Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
- Interventions
- WATCHMAN device
- Device
- Lead sponsor
- Hamilton Health Sciences Corporation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • Fountain Valley, California + 48 more
Location Directory
Clinical trials in Indianapolis, Indiana
This page shows live ClinicalTrials.gov search results for Indianapolis, Indiana, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
8626
Shown on this page
12
Current sort
Recently updated
Location scope
Indianapolis, IN
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 997–1008 of 8,626 matching trials in Indianapolis, IN.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Type 1 Diabetes Mellitus, T1DM, T1D
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 8 Years to 35 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 12
- States / cities
- San Francisco, California • Stanford, California • Aurora, Colorado + 9 more
- Conditions
- Haemophilia A and B With and Without Inhibitors
- Interventions
- Concizumab
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Not listed
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 19
- States / cities
- San Diego, California • Aurora, Colorado • Orlando, Florida + 14 more
- Conditions
- Haemophilia A
- Interventions
- NNC0442-0344 A
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 64 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Indianapolis, Indiana • Iowa City, Iowa + 2 more
- Conditions
- Endometrial Neoplasms
- Interventions
- Pembrolizumab, Carboplatin, Paclitaxel, Placebo for pembrolizumab, Docetaxel, Cisplatin, External Beam Radiotherapy (EBRT), Cisplatin (as radiosensitizer), Brachytherapy
- Biological · Drug · Radiation
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 990 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more
- Conditions
- Opioid Use Disorder
- Interventions
- Tezampanel, Placebo
- Drug
- Lead sponsor
- Proniras Corporation
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone
- Procedure · Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 186
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
- Conditions
- Becker Muscular Dystrophy
- Interventions
- Sevasemten
- Drug
- Lead sponsor
- Edgewise Therapeutics, Inc.
- Industry
- Eligibility
- Male only
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 21 more
- Conditions
- Metastatic Cancer
- Interventions
- Point score prediction tool for 30-day survival
- Diagnostic Test
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 3
- States / cities
- Avon, Indiana • Carmel, Indiana • Indianapolis, Indiana
- Conditions
- Corneal Neovascularization
- Interventions
- 30 minute photoactivation of riboflavin 0.1%, 10 minute photoactivation of riboflavin 0.1%
- Combination Product
- Lead sponsor
- Price Vision Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide, Daratumumab/rHuPH20
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2040
- U.S. locations
- 837
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 526 more
- Conditions
- Multiple Sclerosis, Primary Progressive
- Interventions
- Fenebrutinib, Ocrelizumab, Placebo matched to ocrelizumab, Placebo matched to fenebrutinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 985 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 43
- States / cities
- Homewood, Alabama • Berkeley, California • Fullerton, California + 40 more